CClinicalTrials.gg
RecruitingNCT05692427Updated Mar 15, 2024

Evaluation of Cryotherapy in Granuloma Pyogenicum

An interventional study of Cryopen - Cryotherapy in Granuloma, Pyogenic and Cryotherapy Effect, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Medical University of Graz · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

Surgical excision needs general anesthesia and might have complications due to anesthesia. Cryotherapy can be used in an outpatient setting and doesn't need general anesthesia.

This study will evaluate if cryotherapy works in granuloma pyogenicum with the advancement of no general anesthesia.

02

Conditions studied

  • Granuloma, Pyogenic
  • Cryotherapy Effect

Browse trials for

03

In context

Granuloma

79 studies on the registry are indexed under Granuloma; 8 are open to participants now.

This study's planned enrollment of 200 is above the median of 25 across 56 interventional studies indexed under Granuloma.

Browse Granuloma studies →

Lead sponsor

Medical University of Graz is the lead sponsor of 459 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

diagnosis of granuloma pyogenicum

Exclusion criteria

Exclusion Criteria:

no approvement of cryotherapy

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Cryotherapy

    Cryotherapy on granuloma pyogenicum

    Device: Cryopen - Cryotherapy

Interventions

  • DeviceCryopen - Cryotherapy

    Cryotherapy with N20

06

What researchers measure

Primary outcomes

  1. Recurrence of Granuloma pyogenicum

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Medical University of Graz
    Graz, Styria 8036, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05692427
Lead sponsor
Medical University of Graz
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Jan 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Mar 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion